RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Subscribe To Our Newsletter & Stay Updated
